ChromaDex to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
July 20 2021 - 6:33AM
Business Wire
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a
conference call on Tues., August 3, 2021 at 4:30 p.m. ET to discuss
its financial results for the second quarter ended June 30, 2021.
The financial results will be reported in a press release after the
close of regular stock market trading hours on the same day as the
conference call.
Investor Conference Call:
ChromaDex management will host an investor conference call to
discuss the second quarter results and provide a general business
update on Tues., August 3, at 4:30 p.m. ET.
Participants should call in at least 10 minutes prior to the
call. The dial-in information is as follows:
Date: Thurs., August 3, 2021 Time: 4:30 p.m. ET (1:30 p.m.
Pacific time) Toll-free dial-in number: 1-833-979-2703
International dial-in number: 236-714-2223 Conference ID: 9972229
Webcast link: ChromaDex Second Quarter 2021 Earnings Conference
Call
The conference call will be broadcast live and available for
replay here and via the investor relations section of the Company’s
website at www.chromadex.com.
A replay of the conference call will be available after 7:30
p.m. ET.
Toll-free replay number: 800-585-8367 Replay ID: 9972229
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex delivers Niagen® as the sole active
ingredient in its consumer product Tru Niagen® available at
www.truniagen.com and through partnerships with global retailers
and distributors. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, and Section
21E of the Securities and Exchange Act of 1934. Statements that are
not a description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects," "anticipates," "intends," "estimates,"
"plans," "potential," "possible," "probable," "believes," "seeks,"
"may," "will," "should," "could" or the negative of such terms or
other similar expressions. More detailed information about
ChromaDex and the risk factors that may affect the realization of
forward-looking statements is set forth in ChromaDex's Annual
Report on Form 10-K for the fiscal year ended December 31, 2020,
ChromaDex's Quarterly Reports on Form 10-Q and other filings
submitted by ChromaDex to the SEC, copies of which may be obtained
from the SEC's website at www.sec.gov. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and actual results may differ
materially from those suggested by these forward-looking
statements. All forward-looking statements are qualified in their
entirety by this cautionary statement and ChromaDex undertakes no
obligation to revise or update this release to reflect events or
circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210720005060/en/
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of Finance and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex Media Contact: Alex Worsham, Vice President of Global
Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Sep 2023 to Sep 2024